Biotron (BIT.AX) Stock Price

Biotron Price

ASX·CLOSED
0.00AUD+0.00 (+0.00 %)
Market closed

Over the last 18 years Biotron grew revenue by 4.1% annually, reaching 1.65 M AUD. For Biotron, the net margin of -208.9% is up versus -445.3% a few years ago.

Biotron stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biotron over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotron stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotron's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biotron Stock Price History
DateBiotron Price
7/10/20260.00 AUD
7/9/20260.00 AUD
7/8/20260.00 AUD
7/7/20260.00 AUD
7/6/20260.00 AUD
7/3/20260.00 AUD
7/2/20260.00 AUD
7/1/20260.00 AUD
6/30/20260.00 AUD
6/29/20260.00 AUD
6/26/20260.00 AUD
6/25/20260.00 AUD
6/24/20260.00 AUD
6/23/20260.00 AUD
6/22/20260.00 AUD
6/19/20260.00 AUD
6/18/20260.00 AUD
6/17/20260.00 AUD
6/16/20260.00 AUD
6/15/20260.00 AUD
6/12/20260.00 AUD
6/11/20260.00 AUD
6/10/20260.00 AUD
6/9/20260.00 AUD
6/5/20260.00 AUD
6/4/20260.00 AUD
6/3/20260.00 AUD
6/2/20260.00 AUD
6/1/20260.00 AUD
5/29/20260.00 AUD
5/28/20260.00 AUD
5/27/20260.00 AUD
5/26/20260.00 AUD
5/25/20260.00 AUD
5/22/20260.00 AUD
5/21/20260.00 AUD
5/20/20260.00 AUD
5/19/20260.00 AUD
5/18/20260.00 AUD
5/15/20260.00 AUD
5/14/20260.00 AUD
5/13/20260.00 AUD
5/12/20260.00 AUD
5/11/20260.00 AUD
5/8/20260.00 AUD
5/7/20260.00 AUD
5/6/20260.00 AUD
5/5/20260.00 AUD
5/4/20260.00 AUD
5/1/20260.00 AUD
4/30/20260.00 AUD
4/29/20260.00 AUD
4/28/20260.00 AUD
4/27/20260.00 AUD
4/24/20260.00 AUD
4/23/20260.00 AUD
4/22/20260.00 AUD
4/21/20260.00 AUD
4/20/20260.00 AUD
4/17/20260.00 AUD
4/16/20260.00 AUD
4/15/20260.00 AUD
4/14/20260.00 AUD
4/13/20260.00 AUD
4/10/20260.00 AUD
4/9/20260.00 AUD
4/8/20260.00 AUD
4/7/20260.00 AUD
4/2/20260.00 AUD
4/1/20260.00 AUD
3/31/20260.00 AUD
3/30/20260.00 AUD
3/27/20260.00 AUD
3/26/20260.00 AUD
3/25/20260.00 AUD
3/24/20260.00 AUD
3/23/20260.00 AUD
3/20/20260.00 AUD
3/19/20260.00 AUD
3/18/20260.00 AUD
3/17/20260.00 AUD
3/16/20260.00 AUD
3/13/20260.00 AUD
3/12/20260.00 AUD
3/11/20260.00 AUD
3/10/20260.00 AUD
3/9/20260.00 AUD
3/6/20260.00 AUD
3/5/20260.00 AUD
3/4/20260.00 AUD
3/3/20260.00 AUD
3/2/20260.00 AUD
2/27/20260.00 AUD
2/26/20260.00 AUD
2/25/20260.00 AUD
2/24/20260.00 AUD
2/23/20260.00 AUD
2/20/20260.00 AUD
2/19/20260.00 AUD
2/18/20260.00 AUD
2/17/20260.00 AUD
2/16/20260.00 AUD
2/13/20260.00 AUD
2/12/20260.00 AUD
2/11/20260.00 AUD
2/10/20260.00 AUD
2/9/20260.00 AUD
2/6/20260.00 AUD
2/5/20260.00 AUD
2/4/20260.00 AUD
2/3/20260.00 AUD
2/2/20260.00 AUD
1/30/20260.00 AUD
1/29/20260.00 AUD
1/28/20260.00 AUD
1/27/20260.00 AUD
1/23/20260.00 AUD
1/22/20260.00 AUD
1/21/20260.00 AUD
1/20/20260.00 AUD
1/19/20260.00 AUD
1/16/20260.00 AUD
1/15/20260.00 AUD
1/14/20260.00 AUD
1/13/20260.00 AUD
1/12/20260.00 AUD
1/9/20260.00 AUD
1/8/20260.00 AUD
1/7/20260.00 AUD
1/6/20260.00 AUD
1/5/20260.00 AUD
1/2/20260.00 AUD
12/31/20250.00 AUD
12/30/20250.00 AUD
12/29/20250.00 AUD
12/24/20250.00 AUD
12/23/20250.00 AUD
12/22/20250.00 AUD
12/19/20250.00 AUD
12/18/20250.00 AUD
12/17/20250.00 AUD
12/16/20250.00 AUD
12/15/20250.00 AUD
12/12/20250.00 AUD
12/11/20250.00 AUD
12/10/20250.00 AUD
12/9/20250.00 AUD
12/8/20250.00 AUD
12/5/20250.00 AUD
12/4/20250.00 AUD
12/3/20250.00 AUD
12/2/20250.00 AUD
12/1/20250.00 AUD
11/28/20250.00 AUD
11/27/20250.00 AUD
11/26/20250.00 AUD
11/25/20250.00 AUD
11/24/20250.00 AUD
11/21/20250.00 AUD
11/20/20250.00 AUD
11/19/20250.00 AUD
11/18/20250.00 AUD
11/17/20250.00 AUD
11/14/20250.00 AUD
11/13/20250.00 AUD
11/12/20250.00 AUD
11/11/20250.00 AUD
11/10/20250.00 AUD
11/7/20250.00 AUD
11/6/20250.00 AUD
11/5/20250.00 AUD
11/4/20250.00 AUD
11/3/20250.00 AUD
10/31/20250.00 AUD
10/30/20250.00 AUD
10/29/20250.00 AUD
10/28/20250.00 AUD
10/27/20250.00 AUD
10/24/20250.00 AUD
10/23/20250.00 AUD
10/22/20250.00 AUD
10/21/20250.00 AUD
10/20/20250.00 AUD
10/17/20250.00 AUD
10/16/20250.00 AUD
10/15/20250.00 AUD
10/14/20250.00 AUD
10/13/20250.00 AUD
10/10/20250.00 AUD
10/9/20250.00 AUD
10/8/20250.00 AUD
10/7/20250.00 AUD
10/6/20250.00 AUD
10/3/20250.00 AUD
10/2/20250.00 AUD
10/1/20250.00 AUD
9/30/20250.00 AUD
9/29/20250.00 AUD
9/26/20250.00 AUD
9/25/20250.00 AUD
9/24/20250.00 AUD
9/23/20250.00 AUD
9/22/20250.00 AUD
9/19/20250.00 AUD
9/18/20250.00 AUD
9/17/20250.00 AUD
9/16/20250.00 AUD
9/15/20250.00 AUD
9/12/20250.00 AUD
9/11/20250.00 AUD
9/10/20250.00 AUD
9/9/20250.00 AUD
9/8/20250.00 AUD
9/5/20250.00 AUD
9/4/20250.00 AUD
9/3/20250.00 AUD
9/2/20250.00 AUD
9/1/20250.00 AUD
8/29/20250.00 AUD
8/28/20250.00 AUD
8/27/20250.00 AUD
8/26/20250.00 AUD
8/25/20250.00 AUD
8/22/20250.00 AUD
8/21/20250.00 AUD
8/20/20250.00 AUD
8/19/20250.00 AUD
8/18/20250.00 AUD
8/15/20250.00 AUD
8/14/20250.00 AUD
8/13/20250.00 AUD
8/12/20250.00 AUD
8/11/20250.00 AUD
8/8/20250.00 AUD
8/7/20250.00 AUD
8/6/20250.00 AUD
8/5/20250.00 AUD
8/4/20250.00 AUD
8/1/20250.00 AUD
7/31/20250.00 AUD
7/30/20250.00 AUD
7/29/20250.00 AUD
7/28/20250.00 AUD
7/25/20250.00 AUD
7/24/20250.00 AUD
7/23/20250.00 AUD
7/22/20250.00 AUD
7/21/20250.00 AUD
7/18/20250.00 AUD
7/17/20250.00 AUD
7/16/20250.00 AUD
7/15/20250.00 AUD
7/14/20250.00 AUD
Access this data via the Eulerpool API
Get Free API Key

Biotron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.62 M AUD
-1.61 M AUD
-1.59 M AUD
Jan 1, 2019
1.07 M AUD
-1.70 M AUD
-1.61 M AUD
Jan 1, 2020
803,000.00 AUD
-3.64 M AUD
-3.58 M AUD
Jan 1, 2021
1.46 M AUD
-3.20 M AUD
-3.19 M AUD
Jan 1, 2022
1.56 M AUD
-2.78 M AUD
-2.78 M AUD
Jan 1, 2023
1.43 M AUD
-3.61 M AUD
-3.49 M AUD
Jan 1, 2024
1.65 M AUD
-3.51 M AUD
-3.44 M AUD
Jan 1, 2025
0.00 AUD
-338,800.00 AUD
-318,600.00 AUD

Biotron Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 7:34 PM
 
REVENUEk AUD
GROSS MARGIN%
GROSS INCOMEM AUD
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
2010201120122013201420152016201720182019202020212022202320242025
––––1,000.001,000.001,000.001,000.001,000.001,000.00–1,000.001,000.001,000.001,000.00–
––––-100.00-100.00-100.00-100.00-100.00-100.00–-100.00-100.00-100.00-100.00–
-1.00-1.00-1.00-2.00-1.00-1.00-1.00-1.00-1.00-1.00-2.00-1.00-1.00-1.00-1.00-1.00
-1.00-1.00-2.00-3.00-3.00-2.00-3.00-3.00-1.00-1.00-3.00-3.00-2.00-3.00-3.00–
––100.0050.00–-33.3350.00–-66.67–200.00–-33.3350.00––
0.140.160.230.280.280.300.360.400.450.580.680.720.830.941.031.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biotron generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotron retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotron's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biotron has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotron's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biotron stock margins

The Biotron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biotron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biotron.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
-4.32 %
-99.24 %
-98.22 %
Jan 1, 2019
-4.02 %
-158.55 %
-150.24 %
Jan 1, 2020
-255.84 %
-453.33 %
-445.33 %
Jan 1, 2021
-114.55 %
-219.18 %
-218.50 %
Jan 1, 2022
-81.01 %
-178.32 %
-178.45 %
Jan 1, 2023
-125.84 %
-252.08 %
-244.03 %
Jan 1, 2024
-120.35 %
-213.12 %
-208.89 %
Jan 1, 2025
-120.35 %
- %
- %

Biotron Stock Revenue, EBIT, Earnings per Share

The Biotron earnings per share therefore indicates how much revenue Biotron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2019
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2020
0.00 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2021
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2022
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2023
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2024
0.00 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2025
0.00 AUD
-0.00 AUD
-0.00 AUD

Biotron business model & stock analysis

Biotron Ltd is a company that focuses on the research and development of antiviral drugs. The company was founded in 2000 by Dr. Michelle Miller, who previously worked as a senior researcher in the field of antiviral drug development at a leading pharmaceutical company. Biotron's main business is the development of drugs used to treat viral diseases such as HIV/AIDS, hepatitis B and C, influenza, and Ebola. The company focuses on the development of so-called direct-acting antiviral drugs, which target the virus itself and inhibit its replication. Biotron has made significant progress in the development of such drugs in recent years and currently has several drugs in clinical development. The company works closely with universities, research institutions, and other companies to advance its research and development program. Biotron's business model is based on collaboration with other companies in the field of antiviral drug development. The company works closely with other pharmaceutical companies, hospitals, and government agencies to share its research findings and technologies and bring its drugs to market. The company has two main divisions: research and development, and production and distribution. In the research and development division, Biotron focuses on the development of new drugs that target viruses. The production and distribution division encompasses the production and marketing of these drugs once they are approved for use. As part of its research and development work, Biotron has developed several promising products. One of them is BIT225, a drug used to treat hepatitis C. BIT225 is a direct-acting antiviral drug that targets a specific protein in the virus membrane and inhibits its replication. Another promising product from Biotron is BIT571, a drug used to treat influenza. BIT571 targets a specific type of virus known as Liana or influenza hemagglutinin virus. It has been shown that BIT571 has potent antiviral activity against this type of virus. In addition to BIT225 and BIT571, there are other drugs in clinical development at Biotron. Overall, Biotron has an extensive portfolio of antiviral drugs in various stages of clinical development. In recent years, Biotron has also made significant progress in the production and marketing of its drugs. The company has formed partnerships with other companies in the pharmaceutical manufacturing industry to ensure that its drugs can be produced and brought to market on a large scale. In summary, Biotron Ltd is an emerging company in the field of antiviral drug development. The company has made significant progress in the development of new drugs in recent years and works closely with other companies and research institutions to expand its portfolio. With its promising pipeline of antiviral drugs and strong partnerships with other companies, Biotron has the potential to become a major player in the pharmaceutical industry in the coming years.

Biotron SWOT Analysis

Strengths

Biotron Ltd possesses several key strengths that contribute to its success in the market. These strengths include:

  • Strong intellectual property portfolio: Biotron Ltd holds a significant number of patents and proprietary technologies, providing a competitive advantage in the industry.
  • Expertise in research and development: The company boasts a team of highly skilled scientists and researchers, allowing them to continually innovate and develop cutting-edge products.
  • Established brand reputation: Biotron Ltd has built a strong brand image and reputation for delivering high-quality and reliable products, gaining trust from customers.
  • Diversified product portfolio: The company offers a wide range of products across various therapeutic areas, reducing dependency on a single product or market segment.

Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:

  • Limited market presence: While the company has established its presence in certain markets, it still lacks significant market penetration in other regions or countries.
  • Dependency on key customers: Biotron Ltd relies heavily on a few key customers for a significant portion of its revenue, which exposes the company to the risk of losing those customers.
  • Reliance on external funding: The company heavily relies on external funding sources, making it vulnerable to changes in funding availability or investor sentiment.
  • Regulatory challenges: Biotron Ltd operates in a highly regulated industry, and complying with stringent regulations can pose challenges and delays in product development and approval processes.

Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:

  • Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
  • Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
  • Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
  • Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.

Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
  • Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
  • Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
  • Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.

Weaknesses

Despite its strengths, Biotron Ltd also faces certain weaknesses that can hinder its performance and growth prospects. These weaknesses include:

  • Limited market presence: While the company has established its presence in certain markets, it still lacks significant market penetration in other regions or countries.
  • Dependency on key customers: Biotron Ltd relies heavily on a few key customers for a significant portion of its revenue, which exposes the company to the risk of losing those customers.
  • Reliance on external funding: The company heavily relies on external funding sources, making it vulnerable to changes in funding availability or investor sentiment.
  • Regulatory challenges: Biotron Ltd operates in a highly regulated industry, and complying with stringent regulations can pose challenges and delays in product development and approval processes.

Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:

  • Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
  • Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
  • Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
  • Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.

Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
  • Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
  • Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
  • Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.

Opportunities

Biotron Ltd can leverage certain opportunities in the market to drive its growth and expansion. These opportunities include:

  • Emerging markets: The company can explore and expand into emerging markets with growing healthcare infrastructure and rising demand for innovative pharmaceutical products.
  • Partnerships and collaborations: Biotron Ltd can form strategic partnerships or collaborations with established pharmaceutical companies or research institutes to enhance its research capabilities and market presence.
  • Advancements in technology: Rapid advancements in technology, such as AI and big data analytics, can be leveraged by Biotron Ltd to drive advancements in drug discovery and development processes.
  • Increasing demand for personalized medicine: The growing trend towards personalized medicine opens up new opportunities for Biotron Ltd to develop targeted therapies and companion diagnostics.

Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
  • Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
  • Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
  • Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.

Threats

Biotron Ltd faces certain threats that may pose challenges to its operations and future growth. These threats include:

  • Intense competition: The pharmaceutical industry is highly competitive, with numerous established players and constant entry of new competitors, increasing competitive pressures on Biotron Ltd.
  • Stringent regulatory environment: Changes in regulations or new regulatory requirements can significantly impact the company's operations and increase compliance costs.
  • Patent expiry and generic competition: When patents for Biotron Ltd's products expire, it may face increased competition from generic drug manufacturers, resulting in price erosion and market share loss.
  • Rapid technological advancements: Failure to keep pace with technological advancements in the industry may render Biotron Ltd's products and processes obsolete.

Biotron Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biotron historical P/E ratio, EBIT multiple, and P/S ratio

Biotron annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biotron shares outstanding

The number of shares of Biotron was 999.23 M in 2025. This indicates how many shares Biotron is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
452.06 M Stocks
Jan 1, 2019
577.48 M Stocks
Jan 1, 2020
675.44 M Stocks
Jan 1, 2021
724.76 M Stocks
Jan 1, 2022
828.30 M Stocks
Jan 1, 2023
938.11 M Stocks
Jan 1, 2024
1.03 B Stocks
Jan 1, 2025
999.23 M Stocks
Price targets and forecasts for Biotron are not yet available.

Biotron shareholder structure

% Name
2.69410%
Rookharp Capital Pty. Ltd.
Rookharp Capital Pty. Ltd.
2.42587%
Jey Investment Pty. Ltd.
Jey Investment Pty. Ltd.
2.24520%
Hoy (Michael John)
Hoy (Michael John)
1.90143%
Medway (Michael)
Medway (Michael)
1.03080%
Fordholm Investments Pty. Ltd.
Fordholm Investments Pty. Ltd.
1.00077%
Dulhunty (Angela Fay)
Dulhunty (Angela Fay)

Biotron Executives and Management Board

MM

Dr. Michelle Miller

Managing Director, Executive Director · since 2002

Compensation380,439.00 AUD
PN

Mr. Peter Nightingale

Company Secretary

Compensation84,000.00 AUD
MH

Mr. Michael Hoy

Independent Non-Executive Chairman of the Board

Compensation82,500.00 AUD
RT

Mr. Robert Thomas

(78)

Independent Non-Executive Director

Compensation44,000.00 AUD

Biotron Supply Chain

Biotron Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
GenMark Diagnostics, Inc.
Supplier
-0.66
0.68
0.08
—
—

Frequently asked questions about Biotron

Biotron Ltd. is a biotechnology company specializing in the development of novel antiviral therapies. Their business model focuses on discovering, developing, and commercializing innovative treatments for viral infections. By leveraging their proprietary platform technology, Biotron aims to target specific viruses and inhibit their replication, ultimately leading to the prevention or treatment of viral diseases. With a strong emphasis on research and development, Biotron continuously strives to identify new therapeutic candidates and drive their progression through preclinical and clinical stages. Through strategic partnerships and licensing agreements, Biotron aims to maximize the commercial potential and global reach of their antiviral therapies.

All fundamentals and in-depth analysis of Biotron

Our stock analysis for Biotron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biotron Stock
Biotron Revenue→
Biotron Stock
Biotron Net Income→
Biotron Stock
Biotron P/E→
Biotron Stock
Biotron P/S→
Biotron Stock
Biotron EBIT→
Biotron Stock
Biotron Dividend→
Biotron Stock
Biotron Directors Dealings→
Biotron Stock
Biotron Stocks→
Biotron Stock
Biotron Market capitalization→
Biotron Stock
Biotron Debt→
Biotron Stock
Biotron Liabilities→
Biotron Stock
Biotron Equity→
Biotron Stock
Biotron AAQS→
Biotron Stock
Biotron Employees→
Biotron Stock
Biotron ROE→
Biotron Stock
Biotron ROA→
Biotron Stock
Biotron ROCE→
Biotron Stock
Biotron News→
Biotron Stock
Biotron Analyst Price Targets→

Health Stocks

BioventixBioToxTech CoBioventusBiotonBiovica InternationalBiotequeBioVieBiotechnology AssetsBioXcel TherapeuticsBioteBioxytranBiosynexAll Stocks A–Z →